The co-founder and chief executive officer of MyoGene Bio talked about the advantages of gene editing over traditional gene therapy as a long term treatment for neuromuscular diseases at MDA’s 2023 conference. [WATCH TIME: 3 minutes]
Courtney Young, PhD
Advertisement
Co-founder and chief executive officer of MyoGene Bio.
Articles by Courtney Young, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Anti-MTBR Tau Antibody Etalanetug Given FDA Fast Track Designation
2
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
3
Benzodiazepines and Antipsychotics Tied to Higher Mortality in Hospice Patients With Dementia
4
Incidence and Prevalence of Frontotemporal Dementia Similar to Dementia with Lewy Bodies, Meta-Analysis Shows
5
